论文部分内容阅读
他汀类药物降脂治疗的作用是减少胆固醇(C)在肝脏的合成,并通过竞争性抑制羟甲基戊二酰辅酶A还原酶的活性来表达的。细胞内胆固醇浓度的下降导致肝细胞表面低密度脂蛋白(LDL)受体的表达,其结果是增加了低密度脂蛋白胆固醇(LDL-C)从血液中的排除,减少了血循环中LDL-C的浓度,和其他血脂包括富含甘油三酯(TG)颗粒的载脂蛋白B的下降。最新的指南[1]与以前相比更加强调心血管危险度决定降脂治疗的决择,取消“血脂合适范围”描述;干预靶点:
The effect of statin lipid-lowering treatment is to reduce cholesterol (C) synthesis in the liver and to be expressed by competitively inhibiting the activity of hydroxymethylglutaryl coenzyme A reductase. The decrease in intracellular cholesterol levels leads to the expression of low density lipoprotein (LDL) receptors on the surface of hepatocytes. As a result, LDL-C is increased in the bloodstream and LDL-C , And a decrease in other blood lipids, including triglyceride (TG) -rich particles, apolipoprotein B. The latest guidelines [1] more emphasis than ever before on the decision of cardiovascular risk decision lipid-lowering treatment, the elimination of “blood lipid appropriate range” description; intervention target: